In this line of thought, the development of B-RAF inhibitors stemmed from the observation that the proto-oncogene B-Raf, encoding a serine/threonine protein kinase involved in cell signaling and directing cell growth [4], is mutated in a number of human cancers [5]. This evidence concerns the gene BRAF and cancer.